Tears Substitutions and Their Effects on Higher Order Aberrometery

Sponsor
Gina Rogers (Other)
Overall Status
Withdrawn
CT.gov ID
NCT00812721
Collaborator
(none)
0
1
5
5.9
0

Study Details

Study Description

Brief Summary

Hypothesis is that tear substitutions cause blur after they are instilled. The investigators will use aberrometry as a measurement over time after a tear formulation is used and try to determine if there are any measurable change in higher order aberrations between different tear formulations and how long it takes to return to pre-instillation measurements thus providing information on duration of the tear drop. 4 commercially available "dry eye" artificial tears formulations will be used and preservative saline will act as a control. The study will be conducted on subjects that do not have clinical evidence of dry eye syndrome to focus the data on the blur effects of the tear substitutions.

Condition or Disease Intervention/Treatment Phase
  • Other: Preservative Free Saline
  • Other: Optive
  • Other: Refresh Moderate/Severe
  • Other: Systane
  • Other: Systane Ultra
N/A

Detailed Description

Once consent is obtained the subject will choose from available time slots. Each subject will come to the UIHC Department of Ophthalmology at designated times for approximately one hour on five different days, for a total time commitment of approximately 5 hours. Each subject will receive the same 4 artificial tear substitutes and saline, one different drop each day. One of the four tear substitutes (brands: Systane, Systane Ultra, Optive, and Refresh) will be tested on each of the days. One drop will be used each day and the protocol of each day will be the same, the only factor changing from day to day is the drop that is being evaluated. On each study day, the subject will have a pre-instillation measurement of their higher order aberrometry of each eye. One drop of the designated drop will be placed into each of the eyes. Subsequent aberrometry measurements of each eye will be taken at immediately post-instillation, 5 minutes, 30 minutes and 60 minutes post instillation. The same protocol will be followed with a saline drop and thus each patient will act as a control.

There is no long-term follow-up.

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Supportive Care
Official Title:
Tears Substitutions and Their Effects on Higher Order Aberrometery
Study Start Date :
Jan 1, 2009
Anticipated Primary Completion Date :
Jun 1, 2009
Anticipated Study Completion Date :
Jul 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: 1

Preservative Free Saline

Other: Preservative Free Saline
One drop will be instilled into each eye once

Active Comparator: 2

Optive (TM)

Other: Optive
One drop will be instilled into each eye once

Active Comparator: 3

Refresh Moderate/Severe (TM)

Other: Refresh Moderate/Severe
One drop will be instilled into each eye once

Active Comparator: 4

Systane (TM)

Other: Systane
One drop will be instilled into each eye once

Active Comparator: 5

Systane Ultra (TM)

Other: Systane Ultra
One drop will be instilled into each eye once

Outcome Measures

Primary Outcome Measures

  1. Measurement of a subject's higher order aberrations over time is the primary outcome measure [pre drop instillation, 1, 5, 15, 30, and 60 minutes post instillation]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects that do not have any complaints of dry eye and confirmed by ocular surface disease index questionnaire.

  • Visually correctable to 20/20 in each eye.

  • Non contact lens wearer.

  • No history of systemic disease associated with dry eye syndromes.

  • No current use of ocular medications.

  • Adult volunteers who agree to HIPAA standards and sign informed consent.

Exclusion Criteria

  • Patients that have dry eye symptoms or slitlamp findings consistent with dry eye.

  • Have a systemic condition that is associated with dry eye syndromes.

  • Take systemic medications that have dry as a side effect

  • Currently use artificial tears.

  • Currently are using ocular medications.

  • Currently wear contact lenses.

  • Enrollment of the investigator's office staff, relatives, or members of their respective households.

  • Enrollment of more than one member of the same household.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Iowa Department of Ophthalmology and Visual Sciences Iowa City Iowa United States 52242

Sponsors and Collaborators

  • Gina Rogers

Investigators

  • Principal Investigator: Gina M Rogers, MD, University of Iowa Department of Ophthalmology and Visual Sciences
  • Study Director: Christine Sindt, OD, niversity of Iowa Department of Ophthalmology and Visual Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gina Rogers, Principal Investigator, University of Iowa
ClinicalTrials.gov Identifier:
NCT00812721
Other Study ID Numbers:
  • Iowa RR 01
First Posted:
Dec 22, 2008
Last Update Posted:
Apr 4, 2017
Last Verified:
Mar 1, 2017
Keywords provided by Gina Rogers, Principal Investigator, University of Iowa
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 4, 2017